Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
Authors:
Open Access
- 1 August 2016
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 10, 1509-1519
Abstract
Background: To assess persistence rates of biologic agents for the treatment of rheumatoid arthritis in Japan. Methods: Based on Japanese claims data of 16,214 patients between 2012 and 2014, 6-, 12-, and 18-month persistence rates of different biologic agents were calculated. Determinants of persistence were assessed by means of a multivariate Cox proportional hazard model controlling for age, sex, and comorbidities. A sensitivity analysis was performed with different definitions of persistence and parametric survival analysis. Results: Overall persistence rates in Japan are high and reach 86% after 1 year in the entire sample. The persistence rate for the biologic-naïve subpopulation is above 95%. Persistence is higher for older patients (hazard ratio 0.60 [95% confidence interval 0.40–0.91] for >75 years compared to ≤60 years) and lower for patients with a high comorbidity score (hazard ratio 1.33; 95% confidence interval 1.03–1.70 for Charlson Comorbidity Index score 3–5 compared to ≤2). We found a high variation of persistence between different drugs. Conclusion: Japanese rheumatoid arthritis patients have a high persistence rate of biologic treatments. However, multiple factors affect the persistence rate of Japanese patients, including age, comorbidities, and patient type. Naïve patients tend to have a higher persistence rate than continuing biologic patients.Keywords
This publication has 43 references indexed in Scilit:
- A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 yearsBMJ Open, 2012
- Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target moleculesAnnals of the Rheumatic Diseases, 2012
- A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Preference and Adherence, 2012
- Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2011
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurrent Medical Research and Opinion, 2009
- How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?Archives of Disease in Childhood, 2008
- Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)Modern Rheumatology, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Effect of Personal and Cultural Beliefs on Medication Adherence in the ElderlyDrugs & Aging, 2006